42 results about "Amphetamine" patented technology

A composition and method for treating Attention Deficit / Hyperactivity Disorder (ADHD) is provided which can be used both with and without ethical drugs now used to treat ADHD. The composition contains dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins C, E, B12, B6, B5 and beta-carotene and minerals (calcium, magnesium, zinc and selenium). Ethical drugs such as amphetamines, methylphenidate HCl and pemoline are known to control ADHD, but each has significant side effects when used in their therapeutic dose. When combining the composition with such ethical drugs, the amount of the ethical drug can be lowered below a level which causes undesirable side effects which is an important feature. Preferred compositions contain one or more of lecithin, choline, 5-hydroxytryptophan, tyrosine, Reishi Extract, Kava Extract, Gingko, Ginseng and St. John's Wort.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

A dermal composition for administration of an amphetamine drug comprising a blend of two or more acrylic-based polymers having differing functionalities so as to modulate the drug solubility in the polymer matrix and the delivery rate of the drug, and methods therefor.

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

It is a poison multiple and combination test agent box and its process method, which comprise plastic shell and test paper bar. The plastic shell comprises upper cover and down cover, wherein, the upper cover comprises specimen adding holes, test result display hole and fix mark hole; the down cover is set with flute. The test paper comprises test specimen area, test result display area and water absorption area, wherein, the test specimen area comprises glue gold and filter paper; the test result display area comprises pyroxylin film, C line control area with sheep and rabbit polyclonal antibody, test display area with heroin antigen and test display area with methyl amphetamine antigen. The water absorption area is set with absorption paper and fix mark.

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

The invention relates to an application of a lead compound namely L-corydalmine (L-CDL) of isoquinoline compounds on treating diseases related with addiction. The diseases comprise drug addiction (heroin, opium, methyl amphetamine, morphine, marihuana, cocaine, and the like), nicotine addiction, and alcohol addiction, and also comprise novel drug addiction (stimulant type novel drugs) and brain damage caused by novel drugs.

Process and a test kit for the detection of drugs of methylenedioxy amphetamine family and derivatives, are disclosed. The process comprises (a) sampling sufficient amount of a material, suspected to be examined comprise of said methylenedioxyphenyl group; (b) admixing said sample with a sufficient amount of a strong acid reagent; and (c) detecting color gradual appearance and determining accordingly the presence of said methylenedioxy amphetamine drugs in predetermined interval of time. The test kit comprises a strong acid reagent; a color vs time chart comprising means for the detection of a specific drug by means of color and time of appearance, a reaction chamber wherein suspected material and said strong acid reagent are admixed and color is indicated; a sampler having means to collect sufficient amount of suspected material to be tested and to insert it to the reaction chamber.

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

The invention provides a production method of a novel efficient rat poison which is prepared from the following raw materials in part by weight: 5-50 parts of corn meal or wheat meal or soybean meal, 10-40 parts of bran or fine bran powder, 6-36 parts of industrial paraffin at 60 DEG C, 1-30 parts of rat excrement, 1.0-10 parts of common fish meal, 0.5-10 parts of animal giblets, 0.5-5 parts of animal fat, 0.1-3.0 parts of vegetable oil, 0.01-0.5 part of table salt, 0.01-0.5 part of saccharin, 0.05-0.5 part of amphetamine, 0.001-0.25 part of warfarin or bromadiolone or brodifacoum, 0.001-0.05 part of diethyl ether, 0.001-0.1 part of nitrate or nitrite and 0.01-0.3 part of red pigment or blue pigment. The preparation comprises the steps of sequentially placing the raw materials into a container; stirring for 25-35 minutes at normal temperature under normal pressure to uniformly mix the materials; and preparing the rat poison with a feed granulator.

The present invention is directed to processes for the preparation of lisdexamfetamine and related derivatives, wherein the processes comprise coupling to racemic or enantiomerically enriched amphetamine and wherein the resulting product is advantageously enantiomerically or diastereomerically enriched in the desired stereoisomer.

The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.

The invention generally relates to hapten compounds comprising either (+)methamphetamine or (+)amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+)methamphetamine, (+)amphetamine, or (+)MDMA.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents where the method comprises: (a) administering to a subject a co-therapy treatment with an auricular or peri-auricular electro-acupuncture or neurostimulation device, (b) co-treatment with at least one non-narcotic detoxification agent and (c) administering to the subject an opioid antagonist. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

The invention generally relates to hapten compounds comprising either (+)methamphetamine or (+)amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+)methamphetamine, (+)amphetamine, or (+)MDMA.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating adisease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benignprostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.

The invention discloses an emulsified metal cutting fluid and a preparation method thereof. The emulsified metal cutting fluid is prepared from the following raw materials in parts by weight: 15-70 parts of lauric acid, 40-90 parts of epoxyethane, 5-60 parts of polyacrylic acid, 35-60 parts of nekal, 55-80 parts of fatty acid polyoxyethylene ester, 45-90 parts of ethylene glycol, 45-60 parts of citric acid, 50-80 parts of methyl amphetamine, 20-60 parts of sodium tripolyphosphate, 35-65 parts of sodium borate, 15-70 parts of sodium sulfide, 5-20 parts of diffusant and 10-40 parts of leveling agent. The preparation method comprises the following steps: (1) reacting the citric acid, lauric acid, epoxyethane, polyacrylic acid, nekal and fatty acid polyoxyethylene ester at 80-100 DEG C for 1-2 hours, and cooling to 20-30 DEG C; and (2) adding the rest of components into a closed reaction kettle, uniformly mixing, adding the mixture of the step (1), and stirring uniformly. The emulsified metal cutting fluid has the advantages of high antimicrobial capacity and long shelf life.

The invention relates to a veterinary allylgestrine preparation and a preparation method thereof, belonging to the technical field of veterinary medicine. The veterinary allylgestrine preparation of the present invention is made of raw materials comprising the following mass percentages, 0.3-0.5% allylgestrine, 0.9-1.1% benzyl alcohol, 0.012-0.016% antioxidant, 0.06-0.38% β- Carotene, 0.07~0.25% omega-3 fatty acid. The allylgestrine preparation of the invention has good absorption effect, high bioavailability and good dispersion effect of the preparation.

To provide a d-amphetamine compound, a composition, as well as a process for producing and using the same.SOLUTION: Compositions comprising a d-amphetamine compound, a composition including at least one organic acid covalent bonded to d-amphetamine, salts thereof, derivatives thereof, or combinations thereof are disclosed. Methods for producing and using them are also be disclosed. Organic compounds include heterocyclic nitrogen compounds. Heterocyclic nitrogen compounds are commonly found in nature and are involved in several biological functions in plants and animals. Examples of heterocyclic nitrogen compounds for use in the implementation of the present technology include, but are not limited to, for example, pyridine derivatives, some of which play an important role in the metabolism of nicotinate and tryptophan. In these compounds, one carbon of the phenyl ring is generally replaced by a nitrogen atom.SELECTED DRAWING: None

The invention discloses a rapid detection method for amitraz residue in agricultural products, comprising the following steps: step a, preparing a homogeneous sample to be tested; step b, extracting and concentrating; step c, redissolving; step d, adding phthalate The chloroform solution of formic anhydride is subjected to protection reaction; step e, deprotection reaction to generate xylidine; step f, color reaction; step g, result judgment. The principle of the method of the present invention is simple and easy to understand, with strong specificity, high sensitivity, intuitive detection results, high accuracy of detection results, no need for large-scale analysis instruments, relatively less time-consuming, and extremely low average analysis cost, and is specially suitable for agricultural products. The on-site rapid detection of amitraz residues in Chinese medicine has strong practicability.

A method for non-invasively determining a physiological state of interest in a subject is described. The method involves, placing a body part in contact with a receptor, and directing a source of electromagnetic radiation (EMR) over a range of wavelengths onto body part so that the EMR reaches the blood and interstitial fluid within the body part. The EMR that is absorbed by, reflected by, or transmitted through, the blood and interstitial fluid of the body part is measured, and a spectrum over the range of wavelengths obtained. The spectrum is analyzed to determine an amount of two or more than two analytes within the blood and interstitial fluid of the body part and a biochemical profile is derived. The biochemical profile is used to determine the physiological state of interest in the subject. The physiological state of interest in the subject may be selected from the group of intoxication arising from cannabis, alcohol, a combination of cannabis and alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption.

The invention provides a method for detecting the content of a compound paracetamol and amantadine hydrochloride capsule, and relates to the field of pharmaceutical analysis. The method for detecting the content of the compound paracetamol and amantadine hydrochloride capsule comprises the following steps: (1) taking the content of the compound paracetamol and amantadine hydrochloride capsule, grinding, precisely weighing, putting into a container, adding water for dissolving, diluting to a constant volume, uniformly shaking, filtering, precisely measuring a continuous filtrate, titrating by using a silver nitrate titration solution to the end point by using a potentiometric titration method, and taking out the filtrate to obtain the content of the compound paracetamol and amantadine hydrochloride capsule. Calculating the content of amantadine hydrochloride in the compound paracetamol and amantadine hydrochloride capsule; and (2) taking the content of the compound paracetamol and amantadine hydrochloride capsule, grinding, precisely weighing, placing in a container, adding hydrochloric acid and first water, heating and refluxing, cooling to room temperature, adding second water, inserting the tip of a burette under the liquid level, quickly titrating to the end point by using a sodium nitrite titration solution by using a potentiometric titration method, and calculating the content of paracetamol in the compound paracetamol and amantadine hydrochloride capsule. The detection method provided by the invention has the advantages of good reproducibility, rapidness and no pollution in the detection process.

The invention relates to the technical field of biological detection, in particular to a methylamphetamine detection card for preventing urine samples from being counterfeited as well as a preparation method and application of the methylamphetamine detection card. The methylamphetamine detection card comprises a temperature sensing area, a methylamphetamine detection area and a urine property detection area, wherein the temperature sensing area is used for detecting the temperature of urine, the methylamphetamine detection area is used for detecting the content of methylamphetamine, and the urine property detection area is used for detecting the physicochemical properties of the urine; the detection card can be used for simultaneously detecting the content of methylamphetamine in a urine sample and detecting whether the urine sample is diluted or not, and has higher specificity and sensitivity on the detection of the counterfeiting of the urine sample and the detection of the content of methylamphetamine; the detection card can effectively prevent leak detection caused by the counterfeiting of the urine sample due to dilution and the like, improves the accuracy of methylamphetamine detection, and has important application value in methylamphetamine detection.

Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

A drug-formulating method, a drug commercial-distribution method, and a drug formulation improve safety of a drug that is at risk for abuse—such as methylphenidate, or amphetamine, or an amphetamine-like central-nervous-system stimulant, and particularly a benzodiazepine. The drug is formulated into a form (not a transdermal patch) that tends to deter conversion to powder; and in this form commercially distributed—preferably enclosed in, or dissolved or dispersed into or onto, a nontoxic carrier such as a capsule, for example a gel, e.g., methylcellulose, hydroxymethylcellulose, carbomer polymer, or other gelatinous pharmaceutical agent that is FDA-acceptable. The carrier is preferably water-insoluble, to deter dissolving in water for injection, and may be an oil or a solid—for example paper or other thin medium broadly extended in two dimensions, or a sponge or other medium having generally coarse cellular structure.